Dernières nouvelles
Information non disponible
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
Article de revueLancet Oncol, 2023.
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways
Article de revueCancer Lett, 553 , 2023.
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System
Article de revueAdv Radiat Oncol, 7 (4), 2022.
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Article de revueJ Immunother Cancer, 10 (11), 2022.
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System
Article de revueAdv Radiat Oncol, 7 (4), 2022.
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients
Article de revueClin Genitourin Cancer, 20 (3), 2022.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Article de revueObstet Gynecol Surv, 77 (1), 2022.
Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)
Article de revueKidney Cancer, 5 (1), 2021.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Article de revueN Engl J Med, 385 (20), 2021.
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Article de revueLancet Oncol, 20 (6), 2019.
Projets terminés récemment
- An International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy with Olaparib and Cediranib ... Following a Response to Platinum-Based Chemotherapy , du 2021-01-22 au 2022-01-21